Abstract

Chromium is an essential element involved in the regulation of blood glucose levels. We recently conducted the first pilot trial of chromium supplementation in the new binge-eating disorder (BED). Given the novelty of both BED and chromium supplementation, feasibility studies are essential to address questions regarding the interest in and acceptability of chromium supplementation in this patient population. The current study aimed to understand the overall acceptability of a chromium picolinate (CrPic) intervention for BED, general interest in alternative therapies, barriers to participation, and feasibility of study adaptation. Twenty-one overweight adults with BED completed a 6-month placebo controlled study of CrPic and a 3-month follow-up visit. Participants thought the study was helpful in terms of symptom improvement and reported no barriers to treatment. The results indicate that chromium supplementation for the treatment of BED appears to be feasible and acceptable to participants and that individuals with BED appear generally interested in the use of alternative therapies.

Authors and Affiliations